Momenta Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2017; Provides Revenue Guidance for the First Quarter of 2018
For the year, the company reported total collaboration revenue of $138,882,000 compared to $109,619,000 a year ago. Loss from operations was $92,551,000 compared to $74,727,000 a year ago. Net loss was $88,096,000 or $1.20 per basic and diluted share compared to $21,003,000 or $0.31 per basic and diluted share a year ago.
The company provided revenue guidance for the first quarter of 2018. The company estimates that collaborative reimbursement revenues will be approximately $0 to $2 million per quarter in 2018.